WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use
Weeks 25-28: Retatrutide 8-12 mg weekly + Cagrilintide 1.7 mg weekly
The most commonly reported side effects when taking Neo-B12 Injection include Itching, exanthema (widespread rash), diarrhoea, nausea, vomiting, dizziness, headache, acne, eczematous skin lesions, acne and folliculitis
LPS-free indicates that the AOD9604 peptide has been manufactured to minimize lipopolysaccharide contamination, which can otherwise interfere with metabolic or inflammatory research data
We use single-use vials and needles and store everything to the manufacturers specification
